Micro Medical Solutions Announced Completion of Enrollment in Pivotal STAND Clinical Trial
On December 6, 2023, Micro Medical Solutions (MMS) made an announcement on the completion of a pivotal clinical study enrollment in the United States. MMS microvascular intervention is intended to improve clinical outcomes and quality of life in patients with CLI / CLTI in the US comparing the safety and efficacy of the MicroStent technology to PTA (percutaneous transluminal angioplasty), the current gold standard of treatment. The MicroStent system is already approved for usage in the EEA with a CE mark.
The last patient was enrolled in STAND (a clinical evaluation of Mic...